Direct Compression of 2 mg, 4 mg and 8 mg Tablet Cores Without Prior Granulation

In direct compression, perindopril tert-butylamine is passed through a 500 µm stainless-steel screen together with a portion of lactose monohydrate to break loose agglomerates before the main blending step. Because the active substance is described as slightly hygroscopic in the Pharmacopoeia monograph, the processing room is maintained at or below 35% RH, and excipients are pre-dried to a residual moisture value established in the registered stability dossier. The low-dose component is prepared as a 1:10 preblend with microcrystalline cellulose in a bin blender operated at 10 rpm for 10 minutes; this preblend is then added to the remaining lactose, sodium starch glycolate and croscarmellose sodium and blended for 20 minutes at the same speed. Sodium stearyl fumarate at 0.5–1.0% w/w is used as the lubricant because it allows a shorter blending window than magnesium stearate and reduces the risk of dissolution slowdown at low dose. Final tablet compression is performed on a rotary press fitted with 8 mm round standard concave tooling. Precompression is typically set between 4 kN and 6 kN, with main compression adjusted between 8 kN and 12 kN to produce tablet hardness in the 60–90 N range. In-process limits require friability not more than 1.0% when tested according to Ph. Eur. 2.9.7 and disintegration not more than 15 minutes in purified water at 37°C according to Ph. Eur. 2.9.1.

Content uniformity is assessed on stratified tablet samples using the acceptance value criterion not more than 15 under Ph. Eur. 2.9.40 or USP <905>. The principal process conflict is particle size mismatch between the API and diluents; if agglomerates above 150 µm remain after screening, the risk of segregation and failing content uniformity increases sharply. Direct compression should therefore be limited to API lots whose particle size distribution has been confirmed by laser diffraction using Ph. Eur. 2.9.31. Over-lubrication is controlled by limiting the final lubricant blending step to 3–5 minutes; batches exceeding this window generally show lower dissolution at the 30-minute time point. Release testing for the finished tablets includes assay by liquid chromatography according to Ph. Eur. 2.2.29, related substances according to the Perindopril tert-butylamine monograph, and dissolution in 0.1 M hydrochloric acid using the paddle apparatus at 50 rpm according to Ph. Eur. 2.9.3 or USP <711>. The direct compression route is therefore appropriate only when the API has adequate flow, the environmental dew point is controlled, and the compression run is supported by real-time weight control.

When direct compression blends exhibit segregation at 2 mg perindopril load, dry granulation via roller compaction is selected to stabilise particle size distribution and improve die filling. The API is blended with lactose monohydrate, microcrystalline cellulose, croscarmellose sodium and colloidal silicon dioxide before being compacted on a pharmaceutical roller compactor such as a Gerteis Mini-Pactor or Alexanderwerk WP 120. Ribbon solid fraction is maintained between 0.60 and 0.70, with roll speed and roll gap adjusted to keep the ribbon density within this narrow window because lower solid fraction produces excessive fines and higher solid fraction reduces tablet compressibility. The compacted ribbons are milled through an oscillating granulator fitted with a 0.8 mm or 1.0 mm screen. The resulting granules are blended with extragranular croscarmellose sodium at 2–3% w/w and lubricated with sodium stearyl fumarate at 0.5% w/w for 3 minutes in a tumble blender.

The dry granulation route removes the aqueous massing step and therefore limits hydrolysis of the ester function in perindopril to perindoprilat. This is a critical quality attribute because perindoprilat formation is monitored as a degradation product under the finished-product monograph. Granule particle size is controlled by sieve analysis according to Ph. Eur. 2.9.38, with retention on the 0.8 mm sieve and fines below 75 µm recorded as in-process limits. Compression is performed at main compression forces between 9 kN and 15 kN, and friability remains not more than 1.0% under Ph. Eur. 2.9.7. The route is less sensitive to raw-material particle size variation than direct compression, but it introduces a second processing variable: ribbon density. Batches compacted at ribbon solid fraction below 0.55 tend to produce weak tablets and edge wear, while batches above 0.75 produce hard granules that resist plastic deformation and increase capping tendencies during subsequent compression.

When Low-Dose Capsule Filling Demands Electrostatic and Flow Control

Hard capsule filling of perindopril tert-butylamine is performed after a geometric dilution strategy because the API load per capsule is low, typically in the range of 2–8 mg in a fill weight of approximately 100–150 mg. The API is first blended with lactose monohydrate at a 1:10 ratio in a low-shear drum blender, then this mixture is further diluted to a 1:100 ratio before the remaining excipients are added. HPMC capsule shells are preferred over hard gelatin when moisture uptake is a concern because HPMC shells have a lower equilibrium moisture content, typically 4–6% w/w, compared with 13–16% w/w for gelatin. Capsule filling is carried out on a tamping-pin or dosator machine, such as a Bosch GKF 720, at speeds adjusted to the flow properties of the final blend. Powder bed humidity is maintained in the range of 35–45% RH unless the registered stability data require a lower limit; below 30% RH, electrostatic attraction increases powder adhesion to the dosator pin and can cause variable fill weight.

Lubrication is limited to 0.5% w/w sodium stearyl fumarate or magnesium stearate and is blended for not more than 5 minutes because the capsule fill is not compressed and excess lubricant can retard powder wetting during dissolution. The fill weight is checked at intervals corresponding to not more than 30 minutes of machine run time, and the filled capsules are dedusted and checked for leakage. Dissolution testing is performed with the same 0.1 M hydrochloric acid medium and paddle apparatus as the tablet form, using Ph. Eur. 2.9.3 or USP <711>. The capsule presentation is intended for patients who cannot swallow tablets; however, the formulation must be validated separately because the absence of a compression step changes the contact surfaces and may alter the dissolution profile relative to a direct compression tablet. Any divergence in dissolution at the 15-minute and 30-minute sampling points must be justified by bioequivalence data or a biowaiver where applicable.

Following core compression, aqueous film coating imposes a moisture load onto the perindopril tert-butylamine tablet core, and the coating process must be treated as a controlled stress condition rather than a simple cosmetic step. The tablet cores are charged into a perforated pan coater and preheated until the bed temperature reaches 38–46°C. The coating suspension is sprayed through a two-fluid nozzle at an atomising air pressure between 1.5 bar and 2.5 bar, with inlet air temperature set between 60°C and 75°C and spray rate adjusted to maintain the bed temperature within the specified range. Coating weight gain is maintained at 2–3% w/w of the core weight. The inlet air dew point is controlled below 10°C to reduce the moisture introduced into the pan, and the rotating pan speed is adjusted to prevent tablet attrition while maintaining uniform tablet bed movement.

The central risk in aqueous film coating is core moisture accumulation because perindopril tert-butylamine is slightly hygroscopic and hydrolytically sensitive. Product bed temperatures above approximately 50°C increase the rate of thermal degradation, while prolonged exposure to water during a slow spray process accelerates hydrolysis. For this reason, the coating process is normally completed within 60–120 minutes for a standard batch, and the coated tablets are dried for an additional 10–15 minutes at the lower end of the bed-temperature range after the spray has stopped. Residual moisture is measured by Karl Fischer titration and is held below the threshold specified in the registered dossier. The coated tablets are tested for disintegration not more than 30 minutes under Ph. Eur. 2.9.1, because the film layer delays water penetration, and for dissolution according to Ph. Eur. 2.9.3. The film coat provides light protection and mechanical resistance to edge chipping during packaging, but it cannot compensate for a friable core; core friability must remain not more than 1.0% before coating.

What Changes in Bilayer Compression with Amlodipine Besylate or Indapamide?

Bilayer compression introduces additional interface risks when perindopril tert-butylamine is combined with amlodipine besylate or indapamide in a fixed-dose tablet. The perindopril layer is prepared by direct compression or dry granulation as described for the monolayered tablet, while the amlodipine layer is prepared as a separate granulation because amlodipine besylate shows known contact compatibility and lubricant sensitivity challenges. In the amlodipine layer, sodium stearyl fumarate is used instead of magnesium stearate where the formulation dossier requires it, because amlodipine besylate can undergo degradation in the presence of certain lubricants under moisture stress. The two granulations are fed independently to a bilayer tablet press equipped with two force feeders. First-layer precompression is typically set at 2–5 kN, and main compression is set between 12 kN and 18 kN, depending on the total tablet weight and hardness target. Layer weight is monitored continuously by compression force analysis or by periodic tablet weight and thickness checks, with relative standard deviation controlled below 2.0% for individual layer weight.

For the perindopril/indapamide fixed-dose combination, both actives are low-dose and require rigorous geometric dilution and blend uniformity sampling. Indapamide is usually incorporated at 1.25 mg or 2.5 mg per tablet, and segregation at this low load is controlled by dry granulation rather than direct compression. The finished bilayer tablet is tested for hardness, friability not more than 1.0% according to Ph. Eur. 2.9.7, and content uniformity according to Ph. Eur. 2.9.40 or USP <905>. Dissolution testing must cover both actives and is performed in a medium justified by the registered product specification, commonly 0.01 M hydrochloric acid or 0.1 M hydrochloric acid with paddle apparatus at 50 rpm. Because perindopril contains a secondary amine function, the nitrosamine risk assessment under ICH M7 and the associated regional guidance for chemically synthesised APIs must be completed for both the API and the finished fixed-dose product. The bilayer interface is a potential failure point for capping; process validation includes friability testing after bulk storage and during packaging to detect delayed capping failure.

Parenteral Feasibility and Limits of the Tert-Butylamine Salt in Sterile Use

Injectable use of perindopril tert-butylamine is not a routine commercial configuration because the tert-butylamine salt is designed for solid oral administration, not parenteral delivery. In aqueous solution the salt dissociates, releasing the tertiary-butylamine counterion and exposing perindopril to hydrolytic conversion to perindoprilat, the active diacid metabolite. If a parenteral liquid is required in a clinical or hospital setting, the relevant approach is to use perindoprilat as the active moiety and to formulate it as a sterile solution or lyophilisate, not to inject the tert-butylamine salt directly. Sterile compounding or manufacturing of such a product requires the same controls as other parenteral ACE inhibitors: bacterial endotoxin testing according to Ph. Eur. 2.6.14 or USP <85>, sterility testing according to Ph. Eur. 2.6.1 or USP <71>, and sub-visible particulate control according to USP <790> or Ph. Eur. 2.9.20. Osmolality is adjusted into the physiological range of 270–320 mOsm/kg, and the formulation pH is selected to balance API solubility and chemical stability.

Published data for this specific configuration with perindopril tert-butylamine are limited, so process validation cannot rely on established commercial injectable precedents. The main operational boundaries are that the tert-butylamine counterion is not compatible with generic pH-neutral parenteral vehicles without prior salt conversion, and that aqueous solutions of perindopril are subject to hydrolysis above controlled storage temperatures. Where an injectable product is developed, the drug product must be supported by forced degradation studies under ICH Q1A(R2), elemental impurities data under ICH Q3D, and container-closure compatibility data for the chosen vial or prefilled syringe system. Terminal sterilisation by autoclaving is generally unsuitable for aqueous perindopril-containing solutions because of hydrolytic degradation; aseptic filtration followed by lyophilisation is the more plausible route, but the specific lyophilisation cycle parameters must be generated from product-specific thermal and collapse data.

For dose-adjustable oral granules, dry granulation is preferred over wet granulation because water exposure accelerates hydrolysis of the ester group in perindopril tert-butylamine. The granule formulation is manufactured by roller compaction or by dry mixing followed by slugging on a rotary tablet press, after which the compacted material is milled to a target granule size range of approximately 200–800 µm. A disintegrant such as crospovidone is added at 2–5% w/w so that the granules disperse rapidly when mixed with water or placed on soft food. The granules are filled into sachets made from a moisture-protective laminate such as PET/aluminium/LDPE; this packaging is required because the API is slightly hygroscopic and the sachet presentation exposes a larger surface area to the environment than a compacted tablet. Fill weight per sachet is controlled to maintain the labelled 2 mg, 4 mg or 8 mg dose within the uniformity requirements of Ph. Eur. 2.9.40 or USP <905>.

Granule-filled sachets present a dissolution performance that is more sensitive to granule particle size than compressed tablets, because dissolution begins immediately on dispersion in the mouth or in water. For this reason, the granulation is tested for particle size distribution according to Ph. Eur. 2.9.38, and dissolution is measured in 0.1 M hydrochloric acid with the paddle apparatus at 50 rpm according to Ph. Eur. 2.9.3 or USP <711>. Residual moisture after granulation and sachet filling is controlled by Karl Fischer titration and must remain below the limit defined in the stability dossier. The granule presentation is less common than tablets, but it is used where dose adjustment or swallowing difficulties require a non-tablet oral form. The main process limitation is that granule flow into the sachet filler varies with bulk density; therefore, fill weight is monitored at intervals of not more than 15 minutes and the sachet sealer is qualified for leak integrity after each product-contact material change.